SG11201406141UA - Immortalized stem cells and medicinal composition and medicinal preparation comprising product thereof as active ingredient - Google Patents
Immortalized stem cells and medicinal composition and medicinal preparation comprising product thereof as active ingredientInfo
- Publication number
- SG11201406141UA SG11201406141UA SG11201406141UA SG11201406141UA SG11201406141UA SG 11201406141U A SG11201406141U A SG 11201406141UA SG 11201406141U A SG11201406141U A SG 11201406141UA SG 11201406141U A SG11201406141U A SG 11201406141UA SG 11201406141U A SG11201406141U A SG 11201406141UA
- Authority
- SG
- Singapore
- Prior art keywords
- medicinal
- product
- active ingredient
- stem cells
- immortalized stem
- Prior art date
Links
- 239000004480 active ingredient Substances 0.000 title 1
- 210000000130 stem cell Anatomy 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/067—Hepatocytes
- C12N5/0672—Stem cells; Progenitor cells; Precursor cells; Oval cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1841—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
- A61K38/1866—Vascular endothelial growth factor [VEGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0664—Dental pulp stem cells, Dental follicle stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
- C12N2501/602—Sox-2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
- C12N2501/603—Oct-3/4
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
- C12N2501/604—Klf-4
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
- C12N2501/606—Transcription factors c-Myc
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
- C12N2506/1346—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
- C12N2506/1346—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells
- C12N2506/1361—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells from dental pulp or dental follicle stem cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Developmental Biology & Embryology (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Wood Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2012073594 | 2012-03-28 | ||
JP2012187321 | 2012-08-28 | ||
JP2012275169 | 2012-12-17 | ||
JP2013026886 | 2013-02-14 | ||
PCT/JP2013/059376 WO2013147082A1 (en) | 2012-03-28 | 2013-03-28 | Immortalized stem cells and medicinal composition and medicinal preparation comprising product thereof as active ingredient |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201406141UA true SG11201406141UA (en) | 2014-10-30 |
Family
ID=49260325
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201406141UA SG11201406141UA (en) | 2012-03-28 | 2013-03-28 | Immortalized stem cells and medicinal composition and medicinal preparation comprising product thereof as active ingredient |
Country Status (10)
Country | Link |
---|---|
US (2) | US20150203821A1 (en) |
EP (1) | EP2832851B1 (en) |
JP (1) | JP6010112B2 (en) |
KR (2) | KR101930718B1 (en) |
CN (2) | CN110079503A (en) |
CA (1) | CA2868251C (en) |
IN (1) | IN2014DN08862A (en) |
RU (1) | RU2619221C2 (en) |
SG (1) | SG11201406141UA (en) |
WO (1) | WO2013147082A1 (en) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2940146A4 (en) * | 2012-12-26 | 2016-08-10 | Quarrymen Corp | Highly functional implant material |
JP6166388B2 (en) * | 2014-01-24 | 2017-07-19 | 株式会社Quarrymen&Co. | Pharmaceutical composition for cancer treatment and pharmaceutical preparation for cancer treatment comprising the composition as an active ingredient |
EP3101121B1 (en) * | 2014-01-27 | 2019-12-11 | Beijing Stomatology Hospital, Capital Medical University | Use of genetically modified odontogenic stem cells |
JP2016150919A (en) * | 2015-02-18 | 2016-08-22 | ピアス株式会社 | Cosmetic composition for application |
JP2016210730A (en) * | 2015-05-08 | 2016-12-15 | 上田 実 | Pharmaceutical compositions and production methods thereof as well as pharmaceuticals |
CN105251053B (en) * | 2015-09-23 | 2018-09-04 | 广州赛莱拉干细胞科技股份有限公司 | Cell complex for periodontal tissue repair and application thereof |
WO2017078176A1 (en) * | 2015-11-05 | 2017-05-11 | 株式会社Quarrymen&Co. | Immortalized stem cells, and method for producing same |
JP6830768B2 (en) * | 2016-06-16 | 2021-02-17 | 株式会社Cysay | Wound covering agent and wound covering sheet |
JP6152205B1 (en) * | 2016-08-09 | 2017-06-21 | 仁幸 小林 | Cosmetics, pharmaceutical compositions, and methods for producing them |
CN106267165A (en) * | 2016-08-29 | 2017-01-04 | 楼秀余 | HGH and IGF 1 liposome complex capsule and preparation method thereof |
TWI649422B (en) * | 2016-12-30 | 2019-02-01 | 中國醫藥大學 | Adult multifunctional olfactory stem cells, separation method and application thereof |
FR3068366B1 (en) * | 2017-06-30 | 2023-11-24 | Francais Du Sang Ets | METHOD FOR PRODUCING ERYTHROID PROGENITORS |
WO2019027299A2 (en) * | 2017-08-04 | 2019-02-07 | 주식회사 에스엘바이젠 | Pharmaceutical composition for preventing or treating vascular disorders including mesenchymal stem cell expressing hepatocyte growth factor as active ingredient |
WO2019027298A2 (en) * | 2017-08-04 | 2019-02-07 | 주식회사 에스엘바이젠 | Pharmaceutical composition comprising mesenchymal stem cell expressing trail and cd as effective ingredient for prevention or treatment of cancer |
RU2679082C1 (en) * | 2017-12-13 | 2019-02-05 | Общество с ограниченной ответственностью "Покровский банк стволовых клеток" | Method for extracting a tooth pulp for receiving culture of stem cells |
CN108070567A (en) * | 2018-01-19 | 2018-05-25 | 皓昇莱生物制药有限公司 | A kind of urine derived cell strain of immortalization and its construction method |
JP6923137B2 (en) * | 2018-06-15 | 2021-08-18 | 有限会社大阪空気機械サービス | Tissue healing agent |
KR20200129266A (en) * | 2019-05-08 | 2020-11-18 | 경상대학교산학협력단 | Pharmaceutical composition for preventing or treating male infertility comprising dental tissue-derived mesenchymal stem cells |
CN110951683A (en) * | 2020-01-06 | 2020-04-03 | 深圳华云生物科技发展有限公司 | Preparation method of dental pulp stem cells |
KR102572595B1 (en) * | 2020-12-02 | 2023-08-31 | 충북대학교 산학협력단 | Composition for preventing or treating anti-inflammatory diseases comprising immortalized feline mesenchymal stem cells and their exosome-rich conditoned medium |
KR102456805B1 (en) * | 2020-12-02 | 2022-10-24 | 충북대학교 산학협력단 | Composition for preventing or treating anti-inflammatory diseases comprising immortalized canine mesenchymal stem cells and their exosome-rich conditioned medium |
EP4342478A1 (en) * | 2021-05-19 | 2024-03-27 | Tokyo Medical University | Preventive agent and/or therapeutic agent for bedsores |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5554512A (en) * | 1993-05-24 | 1996-09-10 | Immunex Corporation | Ligands for flt3 receptors |
US20030049236A1 (en) * | 2001-07-27 | 2003-03-13 | Arhus Amt | Immortalized stem cells |
JP3897717B2 (en) * | 2002-04-23 | 2007-03-28 | オリンパス株式会社 | Cell transplantation treatment material and method for producing the same |
WO2006009291A1 (en) | 2004-07-23 | 2006-01-26 | Hitachi Medical Corporation | Method of inducing the differentiation of mesenchymal stem cell into odontoblast cell |
WO2007149548A2 (en) * | 2006-06-22 | 2007-12-27 | Medistem Laboratories, Inc. | Treatment of erectile dysfunction by stem cell therapy |
CN101063150B (en) * | 2007-04-24 | 2010-05-26 | 浙江大学 | Method for transduction of bone marrow mesenchyma stem cell by human telomerase gene |
JP2008307007A (en) * | 2007-06-15 | 2008-12-25 | Bayer Schering Pharma Ag | Human pluripotent stem cell induced from human tissue-originated undifferentiated stem cell after birth |
WO2009057831A1 (en) * | 2007-10-31 | 2009-05-07 | Kyoto University | Nuclear reprogramming method |
US20110151447A1 (en) * | 2007-11-06 | 2011-06-23 | Children's Medical Center Corporation | Method to produce induced pluripotent stem (ips) cells from non-embryonic human cells |
JP5562231B2 (en) * | 2008-07-30 | 2014-07-30 | 国立大学法人京都大学 | Efficient method for establishing induced pluripotent stem cells |
JP2010046019A (en) * | 2008-08-21 | 2010-03-04 | Toyama Univ | Human amnion-derived mesenchymal cell and diabetic medicine using the same |
JP2012502655A (en) * | 2008-09-22 | 2012-02-02 | エイジェンシー・フォー・サイエンス,テクノロジー・アンド・リサーチ(エイ・スター) | Methods for improving differentiation of chondrogenic progenitor cells |
WO2010105257A2 (en) * | 2009-03-13 | 2010-09-16 | The Salk Institute For Biological Studies | Generation of mouse induced pluripotent stem cells bytransient expression of a single non- viral polycistronic vector |
US9487756B2 (en) * | 2009-03-20 | 2016-11-08 | Mesoblast, Inc. | Production of reprogrammed pluripotent cells |
JPWO2011118795A1 (en) * | 2010-03-26 | 2013-07-04 | 国立大学法人名古屋大学 | Injury treatment composition |
JP6132459B2 (en) * | 2011-07-13 | 2017-05-24 | 株式会社 バイオミメティクスシンパシーズ | Prophylactic / therapeutic agent for enteritis containing culture supernatant of mesenchymal stem cells |
-
2013
- 2013-03-28 JP JP2014508058A patent/JP6010112B2/en active Active
- 2013-03-28 KR KR1020177030820A patent/KR101930718B1/en active IP Right Grant
- 2013-03-28 RU RU2014143266A patent/RU2619221C2/en active
- 2013-03-28 IN IN8862DEN2014 patent/IN2014DN08862A/en unknown
- 2013-03-28 CN CN201910232961.8A patent/CN110079503A/en active Pending
- 2013-03-28 KR KR20147029890A patent/KR20150009528A/en active Application Filing
- 2013-03-28 EP EP13769656.3A patent/EP2832851B1/en active Active
- 2013-03-28 SG SG11201406141UA patent/SG11201406141UA/en unknown
- 2013-03-28 CN CN201380027178.9A patent/CN104321426A/en active Pending
- 2013-03-28 WO PCT/JP2013/059376 patent/WO2013147082A1/en active Application Filing
- 2013-03-28 CA CA2868251A patent/CA2868251C/en active Active
-
2014
- 2014-09-27 US US14/499,171 patent/US20150203821A1/en not_active Abandoned
-
2017
- 2017-06-26 US US15/632,831 patent/US10494606B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
EP2832851B1 (en) | 2019-04-17 |
CN110079503A (en) | 2019-08-02 |
CN104321426A (en) | 2015-01-28 |
WO2013147082A1 (en) | 2013-10-03 |
US20170355960A1 (en) | 2017-12-14 |
EP2832851A4 (en) | 2015-09-02 |
JP6010112B2 (en) | 2016-10-19 |
RU2014143266A (en) | 2016-05-20 |
KR101930718B1 (en) | 2018-12-19 |
RU2619221C2 (en) | 2017-05-12 |
KR20150009528A (en) | 2015-01-26 |
CA2868251A1 (en) | 2013-10-03 |
US20150203821A1 (en) | 2015-07-23 |
CA2868251C (en) | 2019-02-12 |
IN2014DN08862A (en) | 2015-05-22 |
US10494606B2 (en) | 2019-12-03 |
KR20170121340A (en) | 2017-11-01 |
EP2832851A1 (en) | 2015-02-04 |
JPWO2013147082A1 (en) | 2015-12-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201406141UA (en) | Immortalized stem cells and medicinal composition and medicinal preparation comprising product thereof as active ingredient | |
HK1255336A1 (en) | Pharmaceutical formulations and processes of preparation thereof | |
IL287381A (en) | Pharmaceutical preparations of human rpe cells and uses thereof | |
HK1205690A1 (en) | Pharmaceutical composition and administration thereof | |
IL238713A0 (en) | Self-regulated release of active pharmaceutical ingredient | |
IL237839A0 (en) | Hydropyrrolopyrrole derivatives, their preparation and pharmaceutical compositions containing them | |
EP2846772A4 (en) | Depot formulations of a hydrophobic active ingredient and methods for preparation thereof | |
IL235414A (en) | Pyrrolotriazinone derivatives, their preparation and pharmaceutical compositions containing them | |
IL230463A (en) | Benzamides, their preparation and pharmaceutical compositions containing them | |
HK1204564A1 (en) | Topical ophthalmological pharmaceutical composition containing axitinib | |
ZA201400336B (en) | Fatty acid composition and plant extract and pharmaceutical preparation and application thereof | |
IL233602A (en) | Benzamide derivatives, their preparation and pharmaceutical compositions containing them | |
IL232577A0 (en) | Morpholinylbenzotriaine derivatives, their preparation and pharmaceutical compositions containing them | |
IL237322A0 (en) | Solid pharmaceutical compositions containing levothyroxine and their preparation | |
IL235955A0 (en) | Benzothiophen derivatives, their preparation and pharmaceutical compositions containing them | |
IL230219A0 (en) | Dihidropyrazole derivatives, their preparation and pharmaceutical compositions containing them | |
HK1208188A1 (en) | Formulations for the delivery of active ingredients | |
HK1204289A1 (en) | Topical ophthalmological pharmaceutical composition containing cediranib | |
IL236466B (en) | Medicament form for release of active ingredients | |
IL238826A (en) | Imidazol-piperidinyl derivatives, their preparation and pharmaceutical compositions containing them | |
EP2926811A4 (en) | Artemether-containing pharmaceutical composition, preparation, and use thereof | |
IL226048A0 (en) | Diphenyl sulfide derivative and pharmaceutical product which contains same as active ingredient | |
IL236870A0 (en) | Hydroxystatin derivatives, their preparation and pharmaceutical compositions containing them | |
IL235550A0 (en) | Depot formulations of a hydrophobic active ingredient and methods for preparation thereof | |
EP2738174A4 (en) | Novel pyrimidine derivative and pharmaceutical composition including same as an active ingredient |